As of November 14, 2026, Tarsus Pharmaceuticals, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from February 18, 2026 to July 13, 2026 (Form 8-K, July 13, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Tarsus Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Tarsus Pharmaceuticals, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-02-18 to 2026-07-13. Every row below is cited to the filing it comes from, and this page adds each new change as Tarsus Pharmaceuticals, Inc. files it.
Also on the record for Tarsus Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G, by FMR LLC | 6.4% of the class | 5%+ stakes | Source |
| September 4, 2026 | Acquired Alkeus Pharmaceuticals, Inc. | $270M | Acquisition | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP Ltd. | 6.5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by JANUS HENDERSON GROUP PLC | 5.3% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 8.46% of the class | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13G/A, by PRUDENTIAL FINANCIAL INC | 4.3% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by Jennison Associates LLC | 4% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by TANG CAPITAL MANAGEMENT, LLC | 2.8% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 7.11% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by RTW Investments, LP | 8.1% of the class | 5%+ stakes | Source |
| July 28, 2025 | Stake report, Schedule 13G, by Deep Track Capital, LP | 5.6% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Tarsus Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Tarsus Pharmaceuticals, Inc. and the records around it.
Tarsus Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Acquisition Sep 2026
- Who owns it
Companies that share a holder
- Jennison Associates LLC also filed stake reports on 14 other companies: LENDINGTREE INC (Oct 2026), PALVELLA THERAPEUTICS INC (Oct 2026), REZOLUTE INC (Oct 2026)
- PRUDENTIAL FINANCIAL INC also filed stake reports on 22 other companies: FrontView REIT, Inc. (Nov 2026), LendingTree, Inc. (Nov 2026), Rezolute, Inc. (Nov 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
Watch Tarsus Pharmaceuticals, Inc.
Get an email when Tarsus Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Tarsus Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Tarsus Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tarsus Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-13 | Reported | not named in the filing | 8-K, 2026-07-13 | ||
| 2026-02-18 | Reported | not named in the filing | 8-K, 2026-02-18 |
New leaders reset buying decisions — get the Full Report on Tarsus Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Tarsus Pharmaceuticals, Inc., with the record behind each one.
Find candidates like senior executive at Tarsus Pharmaceuticals, Inc.Every change, in the filing's words
Reported
On July 13, 2026, Tarsus Pharmaceuticals, Inc. (the "Company") announced that Aziz Mottiwala would be leaving his role as the Company's Chief Commercial Officer and leaving his employment with the Company on July 15, 2026, to pursue a new opportunity as Chief Executive Officer of a public medical device company.
Reported
On February 18, 2026, the Board of Directors (the "Board") of Tarsus Pharmaceuticals, Inc. (the "Company"), upon the recommendation of its Nominating and Corporate Governance Committee (the "Nominating Committee"), expanded the size of the Board from seven to eight directors and appointed David E.I. Pyott to the Board, effective immediately.
- Mr. Pyott will serve as a Class III director with a term expiring at the Company's 2026 annual meeting of stockholders or until his successor is duly elected and qualified.
- Further, effective immediately, the Board appointed Mr. Pyott to serve as Chairperson of the Commercial Committee of the Board and as member of the Nominating Committee as well as the Compensation Committee of the Board.
- The Board has determined that Mr. Pyott is independent under the listing standards of the Nasdaq Stock Market and the rules and regulations of the Securities and Exchange Commission (the "SEC").
- As a non-employee director, Mr. Pyott will receive cash and equity compensation paid by the Company pursuant to its non-employee director compensation policy, as amended, which includes an initial grant with a target grant value of $540,000, with 50% of the award granted as an option to purchase shares of the Company's common stock and 50% of the award granted as RSUs.
Tools for this story
Each opens in a new tab, filled in for Tarsus Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
